Medicus Pharma CEO Discusses AI-Driven Drug Development on Bloomberg World

Dr. Raza Bokhari outlines Medicus Pharma's AI-enabled approach and upcoming catalysts, including Phase 2 data for Skinject.

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Medicus Pharma Ltd. (NASDAQ:MDCX) CEO Dr. Raza Bokhari joined Bloomberg World for a live interview to discuss the company's strategy, the challenges facing biotech stocks, and how artificial intelligence is shaping its drug development efforts. Dr. Bokhari expressed confidence that continued AI-enabled progress, regulatory optionality, and upcoming catalysts, including Phase 2 clinical data readouts for Skinject in the first half of 2026, should materially change investor perception and unlock value.

Why it matters

The interview highlights Medicus Pharma's focus on leveraging AI to accelerate its drug development pipeline, which includes the Skinject program for treating basal cell skin cancer and the Teverelix program for advanced prostate cancer. The company's AI-driven approach and upcoming data readouts could have significant implications for its future growth and investor sentiment.

The details

During the interview, Dr. Bokhari outlined Medicus Pharma's AI-driven approach, positioning the company as a leader in leveraging artificial intelligence to advance its clinical development programs. He discussed how the company's commitment of nearly $14 million of personal capital at $4 per share demonstrates its confidence in the potential of its pipeline, including the upcoming Phase 2 data readouts for Skinject.

  • On February 10, 2026, Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, joined Matt Miller from Bloomberg World for a live interview.
  • Medicus Pharma expects to release topline results for the SKNJCT-003 study in the first quarter of 2026 and secure an end-of-Phase 2 meeting with the FDA in the first half of 2026.

The players

Medicus Pharma Ltd.

A precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets.

Dr. Raza Bokhari

The Executive Chairman and CEO of Medicus Pharma.

Matt Miller

The anchor of Bloomberg World who interviewed Dr. Bokhari.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

Medicus Pharma expects to release topline results for the SKNJCT-003 study in the first quarter of 2026 and secure an end-of-Phase 2 meeting with the FDA in the first half of 2026.

The takeaway

Medicus Pharma's focus on leveraging AI to accelerate its drug development pipeline, including the upcoming Phase 2 data readouts for Skinject, could have significant implications for the company's future growth and investor sentiment in the biotech sector.